Inhibition of PDGFR tyrosine kinase activity by a series of novel N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides – A SAR study on the bioisosterism of pyrimidine and imidazole

Add time:07/15/2019    Source:sciencedirect.com

A series of N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides were synthesized and tested for inhibition of PDGFR and FLT3 autophosphorylation. The novel N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides, obtained by replacement of the pyrimidine system in Imatinib (1) with an imidazole ring, exhibit potent inhibitory activity on PDGFR, similar to the parent compound (IC50 (9e) = 0.2 μM; IC50 Imatinib (1) = 0.3 μM). Selectivity hereby seems to be conserved, as shown by the lack of activity on FLT3, a closely related class III receptor tyrosine kinase, which is not affected by the parent compound Imatinib.

We also recommend Trading Suppliers and Manufacturers of N-[2-(2-nitro-1H-imidazol-1-yl)ethyl]benzamide (cas 36664-11-6). Pls Click Website Link as below: cas 36664-11-6 suppliers

Prev:Syntheses of new imidazole ligand series and evaluation of 1-, 2- and 4,5-imidazole substituent electronic and steric effects on N-donor strengths
Next:Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines)